TY - JOUR
AB - Immune checkpoint inhibitors (ICI) are a standard in cancer therapy, but few patients respond to the treatment. The aim of the present study was the determination of immunological markers for monitoring response to ICI. The present study included 74 patients receiving ICI in subsequent [group 1; non‑small cell lung cancer (NSCLC)] and first‑line setting (group 2; melanoma) and 30 patients with NSCLC receiving first‑line chemotherapy. In groups 1 and 2 β‑2 microglobulin (B2‑MG), neopterin (NPT), IL‑6, IL‑18, HLA‑DRB1 and autoantibodies were assessed after two months of ICI, and before the start of next administration in group 3. In group 1 low level of B2‑MG (P<0.0001), NPT (P<0.0001), IL‑6 (P<0.0001), IL‑18 (P=0.0003), HLA‑DRB1*03 (P=0.016) and anti‑TPO antibodies (P=0.016) were associated with response >six months. In group 2 high level of B2‑MG (P=0.0001), NPT (P=0.0016), IL‑6 (P=0.013) and IL‑18 (P=0.032) were associated with early disease progression (<six months). Univariate analysis demonstrated that immune‑related adverse events were predictive marker of prolonged progression‑free survival (PFS) in group 1 (P=0.038) and 2 (P=0.020). Neutrophil‑lymphocyte ratio ≥5 before immunotherapy was correlated with shorter PFS in melanoma in multivariate analysis (P=0.007). B2‑MG ≥2.5 mg/ml (P=0.006) and NPT ≥12 nmol/l (P=0.027) were predictors of shorter PFS in group 1. B2‑MG ≥2.5 mg/ml was predictor of shorter PFS (P=0.008) in group 2. In group 1 levels of B2‑MG, NPT, IL‑6 and IL‑18 were higher than in group 3. In summary, immunological markers are promising predictive markers for immunotherapy; however, it requires further prospective studies.
AD - Laboratory for Diagnostics of Autoimmune Diseases, Center for Molecular Medicine, Pavlov First Saint Petersburg State Medical University, Saint Petersburg 197022, Russia
Department of Clinical Oncology, Pavlov First Saint Petersburg State Medical University, Saint Petersburg 197022, Russia
Department of Thoracic Surgery, Pavlov First Saint Petersburg State Medical University, Saint Petersburg 197022, Russia
AU - Musaelyan,Aram,A.
AU - Lapin,Sergey,V.
AU - Urtenova,Margarita,A.
AU - Odintsova,Svetlana,V.
AU - Chistyakov,Ivan,V.
AU - Ulitin,Andrey,M.
AU - Akopov,Andrey,L.
AU - Orlov,Sergey,V.
DA - 2022/09/01
DO - 10.3892/etm.2022.11495
IS - 3
JO - Exp Ther Med
KW - immune checkpoint inhibitors
immune‑related adverse events
autoantibodies
HLA‑DRB1
neutrophil‑to‑lymphocyte ratio
peripheral blood biomarker
β‑2 microglobulin
neopterin
interleukin‑6
interleukin‑18
PY - 2022
SN - 1792-0981
1792-1015
SP - 557
ST - Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma
T2 - Experimental and Therapeutic Medicine
TI - Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma
UR - https://doi.org/10.3892/etm.2022.11495
VL - 24
ER -